公开(公告)号：US10324374B2

公开(公告)日：2019-06-18

申请号：US15080714

申请日：2016-03-25

申请人： FUJIFILM Corporation

发明人： Shuhei Yamaguchi ,  Tomotaka Tsuchimura ,  Natsumi Yokokawa ,  Koutarou Takahashi

IPC分类号： G03F7/038 ,  C07C233/36 ,  C07C271/16 ,  C07C271/24 ,  C07C271/34 ,  C07C275/10 ,  C07C275/24 ,  C07C275/26 ,  C07C323/60 ,  C07D211/26 ,  C07D233/32 ,  C07D233/36 ,  C07D235/26 ,  C07D239/10 ,  C07D251/30 ,  C07D403/12 ,  C07D487/04

摘要： There is provided an active light sensitive or radiation sensitive resin composition which contains (A) an alkali soluble resin and (C) a cross-linking agent represented by the following General Formula (1-0).

公开(公告)号：US10294242B2

公开(公告)日：2019-05-21

申请号：US15741893

申请日：2016-07-05

申请人： TP THERAPEUTICS, INC.

发明人： Jingrong J. Cui ,  Evan W. Rogers

IPC分类号： C07D498/18 ,  C07C271/16 ,  A61P35/00

摘要： This disclosure relates to polymorphs of (7S,13R)-11-fluoro-7,13-dimethyl-6,7,13,14-tetrahydro-1,15-ethenopyrazolo[4,3-f][1,4,8,10]benzoxatriazacyclotridecin-4(5H)-one that are useful in the treatment of disease, such as cancer, in mammals. This disclosure also relates to compositions including such polymorphs, and to methods of using such compositions in the treatment of diseases, such as cancer, in mammals, especially in humans.

公开(公告)号：US10233171B2

公开(公告)日：2019-03-19

申请号：US15442475

申请日：2017-02-24

申请人： THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK

发明人： Brent R. Stockwell ,  Scott J. Dixon ,  Rachid Skouta

IPC分类号： C07D213/74 ,  A61K31/47 ,  C07D401/12 ,  C07D309/14 ,  C07C255/58 ,  C07D213/80 ,  C07C271/16 ,  C07C271/24 ,  C07C271/28 ,  C07C205/57 ,  C07C205/58 ,  C07C211/50 ,  C07D239/26 ,  C07C229/60 ,  C07C233/54 ,  C07C237/30 ,  C07D295/088 ,  C07D211/58 ,  C07D295/30 ,  C07D213/36 ,  A61K31/245 ,  A61K31/325 ,  A61K31/351 ,  A61K31/4465 ,  A61K31/495 ,  A61K31/5375 ,  A61K45/06 ,  C07C69/78 ,  C07D295/192 ,  A61K31/27 ,  A61K31/44 ,  A61K31/444 ,  A61K31/4468 ,  A61K31/505 ,  A61K31/506 ,  C07C225/22 ,  C07D239/42

摘要： The present invention provides, inter alia, a compound having the structure: Also provided are compositions containing a pharmaceutically acceptable carrier and a compound according to the present invention. Further provided are methods for treating or ameliorating the effects of an excitotoxic disorder in a subject, methods of modulating ferroptosis in a subject, methods of reducing reactive oxygen species (ROS) in a cell, and methods for treating or ameliorating the effects of a neurodegenerative disease.

公开(公告)号：US20180201577A1

公开(公告)日：2018-07-19

申请号：US15688185

申请日：2017-08-28

申请人： Global Blood Therapeutics, Inc.

发明人： Qing Xu ,  Zhe Li

IPC分类号： C07D207/08 ,  C07D403/06 ,  C07C271/16 ,  C07D401/06 ,  C07D335/02 ,  C07D333/38 ,  C07D309/28 ,  C07D309/08 ,  C07D279/12 ,  C07D265/30 ,  C07D241/04 ,  C07D213/81 ,  C07D211/78 ,  C07D211/60 ,  C07D211/22 ,  C07D211/16 ,  C07D207/48 ,  C07D207/34 ,  C07D401/12

CPC分类号： C07D207/08 ,  C07C271/16 ,  C07D207/34 ,  C07D207/48 ,  C07D211/16 ,  C07D211/22 ,  C07D211/60 ,  C07D211/78 ,  C07D213/81 ,  C07D241/04 ,  C07D265/30 ,  C07D279/12 ,  C07D309/08 ,  C07D309/28 ,  C07D333/38 ,  C07D335/02 ,  C07D401/06 ,  C07D401/12 ,  C07D403/06

摘要： Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.

公开(公告)号：US20180194777A1

公开(公告)日：2018-07-12

申请号：US15741893

申请日：2016-07-05

申请人： TP THERAPEUTICS, INC.

发明人： Jingrong J. CUI ,  Evan W. ROGERS

IPC分类号： C07D498/18 ,  C07C271/16 ,  A61P35/00

CPC分类号： C07D498/18 ,  A61P35/00 ,  C07B2200/07 ,  C07B2200/13 ,  C07C271/16 ,  C07D487/04

摘要： This disclosure relates to polymorphs of (7S,13R)-11-fluoro-7,13-dimethyl-6,7,13,14-tetrahydro-1,15-ethenopyrazolo[4,3-f][1,4,8,10]benzoxatriazacyclotridecin-4(5H)-one that are useful in the treatment of disease, such as cancer, in mammals. This disclosure also relates to compositions including such polymorphs, and to methods of using such compositions in the treatment of diseases, such as cancer, in mammals, especially in humans.

公开(公告)号：US20180016365A1

公开(公告)日：2018-01-18

申请号：US15548053

申请日：2016-03-17

申请人： University of Kansas

发明人： Xueping GE ,  Qiang YE ,  Paulette SPENCER ,  Jennifer Ann CHADWICK

IPC分类号： C08F2/50 ,  A61K6/00 ,  A61K6/083 ,  C07C271/16

CPC分类号： C08F2/50 ,  A61K6/0052 ,  A61K6/083 ,  C07C271/16 ,  C07C271/20 ,  C08F4/00 ,  C08F220/18 ,  C08F2222/225 ,  C08F2220/1858 ,  C08F2222/1013 ,  C08F2222/1093 ,  A61K6/0023 ,  C08L33/10

摘要： The present disclosure relates to tertiary amine co-initiators that demonstrate reduced leaching and which may be utilized in dental restoration and other biomedical applications. Embodiments of the present disclosure provide compounds and compositions for use in preparing polymers and light curable dental resin composites, as well as methods for preparing photocurable polymer-based dental restorative materials. In one or more disclosed embodiments, a co-initiator for use in preparing a polymer comprises a tertiary amine core and two or more pendant, terminal methacrylate groups. In some embodiments, the co-initiator may also act as a co-monomer in a co-polymerization reaction.

公开(公告)号：US20170334908A1

公开(公告)日：2017-11-23

申请号：US15634272

申请日：2017-06-27

申请人： Techfields Pharma Co., Ltd.

发明人： Chongxi Yu ,  Lina XU

IPC分类号： C07D471/04 ,  C07D211/62 ,  C07D207/16 ,  C07C327/30 ,  C07C317/44 ,  C07C271/16 ,  C07C217/60 ,  C07C237/20 ,  C07C237/08 ,  C07C229/58 ,  C07C229/36 ,  C07C219/10 ,  C07D321/12 ,  C07C271/22

CPC分类号： C07D471/04 ,  A61K31/137 ,  A61K31/195 ,  A61K31/197 ,  A61K31/198 ,  A61K31/24 ,  A61K31/277 ,  A61K31/40 ,  C07C217/60 ,  C07C219/06 ,  C07C219/10 ,  C07C219/14 ,  C07C219/28 ,  C07C219/32 ,  C07C229/12 ,  C07C229/36 ,  C07C229/58 ,  C07C237/06 ,  C07C237/08 ,  C07C237/20 ,  C07C271/16 ,  C07C271/22 ,  C07C317/44 ,  C07C327/30 ,  C07C327/36 ,  C07C2602/08 ,  C07D207/16 ,  C07D211/62 ,  C07D321/12 ,  C07D455/02 ,  C07K5/0806 ,  C07K5/0823 ,  A61K2300/00

摘要： One aspect of the invention provides a composition of novel high penetration compositions (HPC) or a high penetration prodrug (HPP) for treatment of Parkinson's disease. The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPCs/HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.

公开(公告)号：US20170291893A1

公开(公告)日：2017-10-12

申请号：US15633894

申请日：2017-06-27

申请人： THE REGENTS OF THE UNIVERSITY OF MICHIGAN ,  EASTERN MICHIGAN UNIVERSITY

发明人： Daniel A. Lawrence ,  Cory Emal ,  Ashley Reinke ,  Shih-Hon Li ,  Mark Warnock ,  Gregory Abernathy

IPC分类号： C07D417/10 ,  C07C275/64 ,  C07C235/80 ,  C07C237/20 ,  C07C243/26 ,  C07D249/08 ,  C07D277/34 ,  C07D209/34 ,  C07C311/48 ,  C07C311/29 ,  C07D207/48 ,  C07D209/08 ,  C07C311/37 ,  C07C271/16 ,  C07C235/34 ,  C07C323/60 ,  C07C69/94 ,  C07D271/113

CPC分类号： C07D417/10 ,  C07C69/84 ,  C07C69/94 ,  C07C233/13 ,  C07C233/56 ,  C07C235/34 ,  C07C235/46 ,  C07C235/80 ,  C07C237/20 ,  C07C243/26 ,  C07C251/76 ,  C07C259/06 ,  C07C271/16 ,  C07C275/64 ,  C07C311/17 ,  C07C311/29 ,  C07C311/37 ,  C07C311/48 ,  C07C311/49 ,  C07C323/60 ,  C07D207/48 ,  C07D209/08 ,  C07D209/34 ,  C07D213/42 ,  C07D249/08 ,  C07D261/18 ,  C07D271/113 ,  C07D277/34 ,  C07D417/04

摘要： The invention relates to plasminogen activator-1 (PAI-1) inhibitor compounds and uses thereof in the treatment of any disease or disorder associated with elevated PAI-1. The invention includes, but is not limited to, the use of such compounds to prevent or reduce thrombosis and fibrosis, to promote thrombolysis, and to modulate lipid metabolism and treat diseases or disorders associated with elevated PAI-1, cholesterol, or lipid levels.

公开(公告)号：US09771316B2

公开(公告)日：2017-09-26

申请号：US14761897

申请日：2014-01-21

申请人： OSAKA UNIVERSITY ,  KNC LABORATORIES CO., LTD.

发明人： Yoshikatsu Kanai ,  Shushi Nagamori ,  Yoshihiko Kitaura ,  Masahiro Neya ,  Naohiro Matsushita

IPC分类号： C07C217/48 ,  C07D215/233 ,  C07D215/26 ,  C07D409/06 ,  C07D405/06 ,  C07D417/06 ,  C07D413/06 ,  C07D403/12 ,  C07C255/54 ,  C07C271/16 ,  C07C271/20 ,  C07D215/22 ,  C07D333/20 ,  C07C211/09 ,  C07D401/12 ,  C07D405/04 ,  C07C317/22 ,  C07C317/28 ,  C07D409/04 ,  C07C217/04 ,  C07C217/72 ,  C07D413/04 ,  C07C323/20 ,  C07C323/25 ,  C07D417/04 ,  C07D263/32 ,  C07D277/28 ,  C07D209/48 ,  C07C255/37 ,  C07D295/08 ,  C07D213/68 ,  C07D307/52

CPC分类号： C07C217/48 ,  C07C211/09 ,  C07C217/04 ,  C07C217/72 ,  C07C255/37 ,  C07C255/54 ,  C07C271/16 ,  C07C271/20 ,  C07C317/22 ,  C07C317/28 ,  C07C323/20 ,  C07C323/25 ,  C07D209/48 ,  C07D213/68 ,  C07D215/22 ,  C07D215/233 ,  C07D215/26 ,  C07D263/32 ,  C07D277/28 ,  C07D295/08 ,  C07D307/52 ,  C07D333/20 ,  C07D401/12 ,  C07D403/12 ,  C07D405/04 ,  C07D405/06 ,  C07D409/04 ,  C07D409/06 ,  C07D413/04 ,  C07D413/06 ,  C07D417/04 ,  C07D417/06

摘要： The invention provides a compound having a selective inhibitory activity against highly-expressed LAT-1 in tumor cell. The compound is represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, and a LAT-1 inhibitor comprising the same.

公开(公告)号：US09718766B2

公开(公告)日：2017-08-01

申请号：US14854616

申请日：2015-09-15

申请人： Techfields Pharma Co., Ltd.

发明人： Chongxi Yu ,  Lina Xu

IPC分类号： A61K31/195 ,  C07C219/06 ,  C07C317/44 ,  A61K31/137 ,  C07C229/36 ,  A61K31/198 ,  A61K31/277 ,  C07C271/16 ,  C07C271/22 ,  C07D321/12 ,  C07C219/10 ,  C07C219/14 ,  C07C219/28 ,  C07C229/12 ,  C07C327/30 ,  C07C229/58 ,  C07D455/02 ,  C07D471/04 ,  C07C237/06 ,  C07C237/20 ,  C07D207/16 ,  C07K5/083 ,  C07D211/62 ,  C07K5/097 ,  A61K31/197 ,  A61K31/24 ,  A61K31/40 ,  C07C219/32 ,  C07C237/08 ,  C07C327/36

CPC分类号： C07D471/04 ,  A61K31/137 ,  A61K31/195 ,  A61K31/197 ,  A61K31/198 ,  A61K31/24 ,  A61K31/277 ,  A61K31/40 ,  C07C217/60 ,  C07C219/06 ,  C07C219/10 ,  C07C219/14 ,  C07C219/28 ,  C07C219/32 ,  C07C229/12 ,  C07C229/36 ,  C07C229/58 ,  C07C237/06 ,  C07C237/08 ,  C07C237/20 ,  C07C271/16 ,  C07C271/22 ,  C07C317/44 ,  C07C327/30 ,  C07C327/36 ,  C07C2602/08 ,  C07D207/16 ,  C07D211/62 ,  C07D321/12 ,  C07D455/02 ,  C07K5/0806 ,  C07K5/0823 ,  A61K2300/00

摘要： One aspect of the invention provides a composition of novel high penetration compositions (HPC) or a high penetration prodrug (HPP) for treatment of Parkinson's disease. The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPCs/HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.